Most Recent
Motorola has slammed Chinese radio manufacturer Hytera's "disruptive and unsatisfactory" request to adjourn a highly anticipated copyright trial over the alleged theft of source code which is due to begin in three weeks.
Billionaire real estate developer Harry Triguboff and his company Meriton have hit back at claims by the former group general counsel of the property giant that he was sacked after refusing to lie, saying the allegations are untenable and untrue.
A former high-flying trader is taking ANZ to court alleging the bank dismissed him for making complaints about attempted manipulation of a key interest rate and not, as the bank claims, for his "offensive" chats with other traders.
A judge has adjourned an interlocutory application because of deficient pleadings in a class action brought against three medical device manufacturers and a former doctor on behalf of thousands of women who claim to have suffered lifelong complications from pelvic mesh implants.
A delegate of IP Australia has tossed opposition by veterinary pharmaceutical company Norbrook Laboratories to a patent by rival animal health specialist Bayer New Zealand for a bovine antiseptic treatment.
A court has appointed provisional liquidators to the IPO Wealth Group, rejecting claims by the firm's sole director that the move would severely damage his reputation and that of the wider Mayfair group.
Supermarket giant Woolworths has been hit with a $1 million infringement notice from the Australian Communications and Media Authority for what the regulator called "significant breaches" of spam laws.
Police have arrested Titus Day, the former manager of pop star Guy Sebastian, over allegations he duped the singer out of $1.15 million over seven years.
The company that operates the Newmarch House nursing home in Sydney is facing a possible class action after a coronavirus outbreak at the facility resulted in the deaths of 19 residents.
Drug manufacturer Janssen wants to expand its high stakes case against Juno Pharmaceuticals over its HIV drug Prezista, alleging Juno's plans to launch a generic version of the drug threaten another one of its patents.